Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What promo?
Was a good stepping stone for a while when the rumours were flying.
GAP
I don't get it either. I'll stick with GAP. lol
I would only short OPC at 2
The big boys will drive it down to get their price.
IAE still super cheap and I'm going to buy more (again) I hope.
I don't know anything about biotech but I think its a screaming buy!
OPTI was such a great trade for me earlier in the year. Glad I got out of it though...
CALGARY, June 25 /CNW/ - OPTI Canada Inc. (OPCDF:$2.0000,$0.0000,0.00%) ("OPTI" or the "Company") is providing an update on its previously announced public offering (the "Offering") of common shares (the "Common Shares") conducted through a syndicate of underwriters led by TD Securities Inc., Credit Suisse Securities (Canada), Inc. and RBC Capital Markets as joint bookrunners, together with Scotia Capital Inc., CIBC World Markets Inc., FirstEnergy Capital Corp., HSBC Securities (Canada) Inc. and National Bank Financial Inc. (the "Underwriters"). After conducting a broad, overnight marketed offering that was fully subscribed, OPTI reached an agreement with its Underwriters yesterday morning to issue 88,250,000 Common Shares at a price of $1.70 per share ("Offering Price") for total gross proceeds of approximately $150 million. OPTI also agreed to grant the Underwriters a 15% over-allotment option.
You know John, I just had a feeling about this one. I'm going to wait on it and see what happens. The NCI results should create some interest if they are positive.
It was supposed to be up 10 cents by now! I'm going to have to take that Beamer back to the dealership. I wonder if I can return my GAP UP licence plate?
I won't tell you how much I'm up with GAP on 1 cent. (g)
S up 5% GAP up 6% lol
No kidding. Timing is everything.
Bring on the NCI results!
I can't get excited about that one.
Sure, I'll get right on that.
Didn't know they covered biotech.
Sure. Coffin Bro recommendation as well by the way.
GMI
Drill results expected soon
Good intercepts of sulphides in core
Chairman just bought 140000 shares on the open market
Lets pray for rain so you can make some beer in the fall!
You got something growing Johnny?
Just getting started looks like.
What do you know about GAP promotion?
Well they better pump it then so I can sell my 10 cent shares for 20 cents!
Nope. Had never heard of it until a week ago.
GRI up 27% today. Waaaaaaaaaaaaaaaaaaaaaa!!!!!!!!!!
Hi, there's a small Canadian biotech with a drug being tested at the NCI (National Cancer Institiute) in Bethesda, Maryland. Name is Pharmagap and the symbol is GAP on the TSXV. Trades in the States under the symbol PHRGF. Previous tests done on human cancer cells in mice showed their lead drug was effective in treatment of cancer (see below). Results from NCI expecting sometime in the next 4 weeks.
PharmaGap Drug Effective Against Breast And Colon Cancer
Ottawa, Ontario/April 17, 2008 - PharmaGap Inc. (TSX-V: GAP) ("PharmaGap" or "the Company") released today the results of animal studies indicating statistically significant effectiveness of its lead cancer drug, PhG-alpha-1, in treating human breast and colon cancer.
Five separate test models, with a total of 240 mice, having previously been implanted with either human breast or colon cancer, were treated with PhG-alpha-1 at three doses, both singly and in combination with chemotherapeutic agents, or received saline solution or the chemotherapeutic agent alone as test controls.
In two of the test groups, one breast and one colon, the human cancer cells were implanted intravenously (breast) or intraperitoneally (colon), in order to simulate the natural metastases or spreading of the cancer cells within the body from one host organ to another. At the completion of a seven day period during which the cancer cell types used are known to establish tumours, the treatment regime began.
In three of the test groups, one breast and two different colon cell types, the human cancer cells were implanted subcutaneously. Once one or more palpable tumours were established, treatment began on a mouse by mouse basis, according to its assigned treatment group.
Breast cancer metastatic model
In this model, human breast cancer of the type Estrogen Receptor negative, which as a group represent the 30% of breast cancers which are not currently treatable by available drug therapies, were implanted into the bloodstream and provided with a seven day period to allow tumours to form. The type of cancer cells implanted is known to be highly invasive to the lungs, within a 3 to 5 day period following implantation. Following this establishment period of seven days, the treatment regime began in the eight groups of five mice.
In the group of 5 mice receiving PhG-alpha-1 at the dose of 1 mg/kg body weight, 4 of 5 (80%) when euthanized at the end of the trial period were observed to be tumour-free on post mortem examination, with no effect on other organs. The remaining mouse had developed a single small, friable (easily broken down) tumour. In the two control groups (saline and chemotherapy alone), 9 of 10 (90%) developed tumours, with only one surviving to the end of the trial and with ancillary organ damage to some degree. For all other treatment groups, 22 of 25 (88%) developed tumours, and none survived to the end of the trial, again exhibiting ancillary organ damage.
Breast cancer subcutaneous model
Using the same human breast cancer type, cancer cells were implanted beneath the skin and provided time to develop palpable tumours, following which treatment began.
In both single and combination therapy with a low dose of conventional chemotherapy agent, PhG-alpha-1 at 1 mg/kg body weight extended mouse survival relative to controls. In the cohorts receiving the combination treatment, the 5 and 10 mg/kg dosages showed however a longer extension of survival. More significantly, the cohorts receiving PhG-alpha-1 at each of the three dosing levels in the combination treatment showed a clear reduction in tumour volume compared to the cohort receiving chemotherapy alone, with a statistically significant dose response. The overall reduction in tumour volume compared to the control group receiving chemotherapy alone was approximately 58.7%.
Colon cancer metastatic model
Human colon cancer cells type LS180, known to be highly metastatic following implantation in the peritoneal cavity (the space containing the intestines, stomach and liver), were provided with a period of seven days in order to establish metastatic tumours on the liver, spleen, and other sites within the cavity. PhG-alpha-1 was administered intraperitoneally at three doses (1, 5, and 10 mg/kg body weight), alone and in combination with a conventional chemotherapeutic agent at sub-therapeutic dose, over up to a 98 day period. In the group receiving PhG-alpha-1 alone at the 10 mg/kg dose, an improvement in survival relative to the control group was observed from day 50 to 80. In the group receiving PhG-alpha-1 at 10 mg/kg in combination with chemotherapy, survival relative to the group receiving chemotherapy alone was evident throughout the test period.
Overall tumour incidence was 46% in the groups receiving PhG-alpha-1 alone, at all dosages, compared with 80% in the saline control group, and was 60% in groups receiving PhG-alpha-1 in combination therapy, compared to 100% for the chemotherapy control.
Measurement of VEGF serum levels (vascular endothelial growth factor, an angiogenic (growth of blood vessels) agent increasing tumour malignancy) confirmed earlier results showing reduction in VEGF levels following treatment with PhG-alpha-1.
Additional models
Analysis of data from two additional models using two different human colon cancer cell lines continue and results will be announced as they become available over the course of the next few weeks.
Previous tests showed the drug's effectiveness in delaying the ability of human cancer cells to form tumours in mice, when administration of PhG-alpha-1 alone or in combination with chemotherapeutic agents began immediately following the introduction of the cancer cells to the mouse test subject. The current round of testing just completed - known as an Established Tumour Study ("ETS") - mimics the therapeutic treatment regime found in clinical treatment of humans, in that the drug treatment regimen is commenced only after tumours are allowed to develop without treatment.
These test results provide positive indication that PhG-alpha-1 has the ability to be developed into an effective agent against cancer in test models designed to mimic real world therapy regimes encountered in clinical treatment of humans.
About PharmaGap Inc.
PharmaGap Inc. (TSX-V: GAP), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel therapeutic compounds for the treatment of cancer. PharmaGap's research platform targets cellular signaling pathways controlled by protein kinase C (PKC) isoforms. PharmaGap's lead drug compound, PhGalpha1, is in preclinical development. The Company's strategy is to out-license drug compounds to larger life sciences companies at the preclinical stage. For more information please visit the Company's website at www.pharmagap.com.
For information relating to this release, please contact:
Robert McInnis, President & CEO
(613) 990-9551 bmcinnis@pharmagap.com
PharmaGap to raise $861,920 to advance drug compounds
2009-06-17 08:17 ET - News Release
Mr. Robert McInnis reports
PHARMAGAP ANNOUNCES COMPLETION OF $861,920 PRIVATE PLACEMENT OF SHARES AND WARRANTS
PharmaGap Inc. has arranged a non-brokered private placement financing of 5,387,000 equity units consisting of common shares and warrants to purchase common shares. The price per unit was 16 cents, for total proceeds of $861,920. Warrants have a two-year term and an exercise price of 20 cents per share. The shares issued pursuant to the private placement and subsequent warrant exercise are subject to a four-month restriction from trading on the TSX Venture Exchange, in accordance with TSX-V rules and regulations for equity private placements.
Proceeds from this private placement will be used to further advance PharmaGap's portfolio of drug compounds, for investor relations activities and for general working capital.
PharmaGap has engaged Capital Street Group Investment Services Inc., a limited market dealer registered with the Ontario Securities Commission, to act as its lead broker for this offering.
Capital Street Group was paid a cash fee for advisory and structuring services equal to 6.75 per cent of the gross proceeds, which amounts to $58,180, and 363,622 warrants on the same terms as the private placement. Capital Street Group was also paid a total of $48,154 (5.6 per cent of gross proceeds) plus 275,695 warrants for finders fees for its distribution group. Northern Securities was paid $16,800 (1.9 per cent of gross proceeds) plus 105,000 warrants as finders fees.
The private placement has been filed under the TSX-V expedited private placement filing system.
Time to revive this thread?
Which species? Lake fishing?
How was the fishing?
1 in 3000 chance they hit the big one.. Waaaaaaaaaa!!!!!!!!
GALORE TO DRILL KEY TARGETS IN MEXICO
Vancouver, B.C., Galore Resources Inc. (GRI-TSX-V) announces the commencement of a 3,500-metre reverse-circulation drill program to test known gold targets on its Dos Santos Gold project in northern Zacatecas State, Mexico.
The 100%-owned, 14,000-hectare property is in the historic Concepcion del Oro mining district, 35 kilometres south-east of Goldcorp’s massive Peñasquito mine and adjacent to the northern boundary of Canplats recent Camino Rojo gold discovery.
The program is scheduled to commence July 1st and will drill-test known epithermal gold targets and a vein system hosted in calc-silicate altered rocks. Galore is conducting a prospecting, mapping and soil geochemical survey in areas of the property which are potential hosts for the Peñasquito and Camino Rojo style sedimentary hosted gold-silver-lead-zinc mineralization.
In 2008, Galore completed an extensive exploration program that included systematic trench sampling which resulted in a significant number of samples containing anomalous gold and gold pathfinder elements. Several samples exceeded 1,000 ppb gold (one gram), with the highest result being 208 grams of gold per tonne over 0.5 metres.
The Dos Santos exploration program is being managed by Octavio Gonzalez, Galore’s Vice President of Exploration for Mexico. Uwe Schmidt, P. Geo., Vice President Exploration and Galore’s Qualified Person as defined by Canada’s National Instrument 43-101, is responsible for supervising the Dos Santos program and has verified the technical data in this release.
Galore Resources is a British Columbia-based exploration company that has assembled a leading group of industry professionals to acquire and explore for promising deposits with an emphasis on gold in Mexico and base metals in British Columbia.
To find out more about Galore Resources visit our website at www.galoreresources.com
GALORE RESOURCES INC.
“Michael W. Byrne”
President
For progress updates and queries on Galore Resources Inc. (TSX.V -GRI) please contact:
Erica C. Bearss,
Vice-President, Corporate Communications
Email: ebearss@galoreresources.com
Tel.: 604-647-2298
Fax: 604-647-008
GALORE TO DRILL KEY TARGETS IN MEXICO
Vancouver, B.C., Galore Resources Inc. (GRI-TSX-V) announces the commencement of a 3,500-metre reverse-circulation drill program to test known gold targets on its Dos Santos Gold project in northern Zacatecas State, Mexico.
The 100%-owned, 14,000-hectare property is in the historic Concepcion del Oro mining district, 35 kilometres south-east of Goldcorp’s massive Peñasquito mine and adjacent to the northern boundary of Canplats recent Camino Rojo gold discovery.
The program is scheduled to commence July 1st and will drill-test known epithermal gold targets and a vein system hosted in calc-silicate altered rocks. Galore is conducting a prospecting, mapping and soil geochemical survey in areas of the property which are potential hosts for the Peñasquito and Camino Rojo style sedimentary hosted gold-silver-lead-zinc mineralization.
In 2008, Galore completed an extensive exploration program that included systematic trench sampling which resulted in a significant number of samples containing anomalous gold and gold pathfinder elements. Several samples exceeded 1,000 ppb gold (one gram), with the highest result being 208 grams of gold per tonne over 0.5 metres.
The Dos Santos exploration program is being managed by Octavio Gonzalez, Galore’s Vice President of Exploration for Mexico. Uwe Schmidt, P. Geo., Vice President Exploration and Galore’s Qualified Person as defined by Canada’s National Instrument 43-101, is responsible for supervising the Dos Santos program and has verified the technical data in this release.
Galore Resources is a British Columbia-based exploration company that has assembled a leading group of industry professionals to acquire and explore for promising deposits with an emphasis on gold in Mexico and base metals in British Columbia.
To find out more about Galore Resources visit our website at www.galoreresources.com
GALORE RESOURCES INC.
“Michael W. Byrne”
President
For progress updates and queries on Galore Resources Inc. (TSX.V -GRI) please contact:
Erica C. Bearss,
Vice-President, Corporate Communications
Email: ebearss@galoreresources.com
Tel.: 604-647-2298
Fax: 604-647-008
Okay, you don't have to rub it in.
Appleton Exploration Inc. Intersects 192 gpt Au (6.17opt) Over 10 Metres at Manalo
Last Update: 6/15/2009 9:00:31 AM
VANCOUVER, BRITISH COLUMBIA, Jun 15, 2009 (Marketwire via COMTEX) -- Appleton Exploration Inc. (AEX) has received further gold assay results from the 2009 reverse circulation drilling program on the Manalo Gold Project in the Republic of Mali, West Africa. MDL-09-056 has returned 192 grams per tonnes Au (6.17oz/t) over a 10 metre quartz rich zone including 640 gpt Au (20.58oz/t) over 3 metres. These values were confirmed in the lab QA/QC checks, which gave values of 148 gpt Au over 10 metres, including 493 gpt Au over 3 metres. Appleton has requested a second re-assay of the pulps, a resplit of the coarse rejects and also has submitted a second split from the original reverse circulation field samples for the 3 metre interval.
The intercept appears to be a new zone 50 metres to the east of the intercept in previously reported drill hole DL-36 of 15.64 gpt over 16.0 metres. The azimuth of MDL-09-056 was drilled perpendicular to the interpreted trend of mineralization in this sector of the permit and at a dip of -55 degrees. The intercept is near surface, between 53.0 and 63.0 metres down hole. Company geologists are working on interpretations and correlations with other holes. Assays for the remaining holes for the 2009 reverse circulation program are pending.
"With such a spectacular near surface intercept, the Manalo project is looking extremely encouraging," states Appleton President Tim Henneberry.
The drilling program is being conducted under the supervision of Mr. Christopher J. Wild, P. Eng., a Qualified Person as defined in National Instrument 43-101. QA/QC protocols of standards, duplicates and blanks are being incorporated in the sampling program. Assaying is being completed by ALS Chemex in Bamako, Mali.
Appleton is earning a 100% interest in the Manalo Gold Project, subject to a 2% Net Smelter Return (NSR) Royalty, from Delta Exploration Inc. ("Delta") a wholly-owned subsidiary of Rockgate Capital Corp. (RGT).
About Mali
Mali is the fastest growing gold producing country in Africa. Production in 2007 amounted to 2 million ounces of gold, making Mali Africa's third-largest gold producer after South Africa and Ghana. AngloGold Ashanti Limited, one of the largest gold mining companies in the world, has interests in three operating mines in Mali: Sadiola, Yatela and Morila.
On Behalf of the Board of Directors,
R.Tim Henneberry, P.Geo., President and CEO
R. Tim Henneberry, P.Geo., President and Director of Appleton Exploration Inc., is the Qualified Person as defined in National Instrument 43-101, who has reviewed and approved the technical content of this news release.
GRI is my next penny pick. Get em while they're cheap!
You recover yet or are you still in withdrawal?
I think we all have stories like that Kastel. Too many of them.
Anybody got GRG? Sure looks like somethings cookin'